MedPath

CSPC Pharmaceutical Gains Approval for New Diabetes Drug

CSPC Pharmaceutical Group has received marketing approval from China’s National Medical Products Administration for its new diabetes drug, Prusogliptin Tablets, branded as Shanzeping, aimed at improving glycemic control in adults with type 2 diabetes.

CSPC Pharmaceutical Group has announced the receipt of marketing approval from China’s National Medical Products Administration for its new chemical drug, Prusogliptin Tablets, branded as Shanzeping. This innovative drug is designed to enhance insulin secretion and lower blood glucose levels, providing a new treatment option for adults with type 2 diabetes. The approval of Shanzeping not only marks a significant milestone for CSPC Pharmaceutical Group in the field of metabolic diseases but also enriches the company’s product portfolio. CSPC Pharmaceutical Group, based in Hong Kong, specializes in the development and production of pharmaceutical products, with a focus on innovative drugs and healthcare solutions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

CSPC Pharma's Leuprorelin Injection and Regorafenib Tablets Approved for Clinical Trials and Treatment in China

CSPC Pharmaceutical Group's Leuprorelin Extended-Release Injection has been approved for clinical trials in China for solid tumors, marking a significant advancement in long-acting GnRH agonists.

CSPC Pharmaceutical's Nano-Formulation SYHX2011 Approved in China for Advanced Breast Cancer

CSPC Ouyi Pharmaceutical's SYHX2011, a nano-formulation drug, has received marketing approval from China’s National Medical Products Administration for advanced breast cancer treatment.

CSPC Pharmaceutical Advances Hypertension and Obesity Treatments with Novel Drug Approvals

CSPC Pharmaceutical's SYH2062 Injection, a siRNA drug, has been approved for clinical trials in China, targeting hypertension with a potential six-month dosing interval.

SSY Group Receives Approval for Compound Sodium Acetate and Glucose Injection in China

SSY Group has secured approval from China's National Medical Products Administration for its Compound Sodium Acetate and Glucose Injection.

China's NMPA Accepts Ascentage Pharma's NDA for Lisaftoclax in R/R CLL/SLL with Priority Review

Ascentage Pharma's NDA for lisaftoclax, a novel Bcl-2 inhibitor, has been accepted and granted priority review by China's NMPA for relapsed/refractory CLL/SLL.

Shandong Xinhua Pharmaceutical Receives Approval for Generic Cefuroxime Axetil Dispersible Tablets in China

Xincat Pharmaceutical, a subsidiary of Shandong Xinhua Pharmaceutical, has received approval from China’s National Medical Products Administration for its cefuroxime axetil dispersible tablets.

Shandong Xinhua Pharmaceutical Receives Approval for Pentazocine

Shandong Xinhua Pharmaceutical has received approval for pentazocine, expanding its portfolio of pain management drugs.

Dupixent Approved in China as First Biologic for COPD Patients

The NMPA in China approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD with raised blood eosinophils.

CSPC Pharmaceutical Receives Approval for New Hypertension Drug Trials

CSPC Pharmaceutical has received approval to commence clinical trials for its novel hypertension drug, marking a significant step in its development program.

Glecirasib Receives Breakthrough Therapy Designation in China for Pancreatic Cancer

Jacobio Pharma's glecirasib, a KRAS G12C inhibitor, has been granted Breakthrough Therapy Designation (BTD) by China's CDE for pancreatic cancer.

Reference News

[1]
CSPC Pharmaceutical Gains Approval for New Diabetes Drug - TipRanks.com
tipranks.com · Jan 13, 2025

CSPC Pharmaceutical Group received China's approval for Prusogliptin Tablets (Shanzeping), a new treatment for type 2 di...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy